CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
OS by PS in Metastatic Pancreatic Cancer Treatment- Data From an Exploratory Subgroup Analysis
<< View More Conferences
2016 SNO Annual Meeting
Oncology Conference Multimedia
View more videos >>
Dr. Ahluwalia on Using Precision Medicine to Treat Brain Metastases
Dr. Iavarone on the Role of the ID2 Protein in Brain Cancer
Dr. O'Connell on a Phase II Trial to Evaluate Optune in Grade III Brain Cancer
Oncology Conference Articles
Phase II Trial Looks to Study Optune's Efficacy in Grade III Recurrent Glioma
Researchers are hoping that a proposed phase II study exploring use of the Optune system in patients with recurrent grade III malignant glioma will expand the indications for the tumor treating fields (TTFields) device beyond its current FDA-approved use in recurrent grade IV glioblastoma.
Nivolumab/Radiotherapy Combo Well-Tolerated in Newly Diagnosed GBM
Treatment with nivolumab and radiotherapy with or without concurrent temozolomide was well tolerated and showed promising signs of efficacy for patients with newly-diagnosed glioblastoma multiforme.
Durvalumab Shows Durable Activity in Recurrent GBM
The PD-L1 inhibitor durvalumab generated durable responses in bevacizumab-naïve patients with recurrent glioblastoma multiforme.
AG-120 Shows Early Efficacy in IDH1-Mutant Glioma
Treatment with AG-120 at an established dose of 500 mg induced a stable disease rate of 83% and a minor response rate of 9% for patients with non-enhancing
Optune Survival Benefit in GBM Sustained With Long-Term Data
Updated data from the phase III EF-14 study showed that adding Optune to temozolomide improved overall survival by 4.8 months compared with temozolomide alone in patients with newly diagnosed glioblastoma multiforme.
Pembrolizumab Shows Durable Benefit for PD-L1-Positive Recurrent GBM
Pembrolizumab had a 6-month progression-free survival rate of 44% and a manageable safety profile for patients with recurrent PD-L1-positive glioblastoma multiforme.
Checkpoint Inhibitors Show Promise in Glioblastoma
Findings from the phase II trials KEYNOTE-028 of pembrolizumab and MEDI4736 (durvalumab) point to a role for checkpoint inhibitors in the treatment of glioblastoma multiforme, based on encouraging efficacy signals and safety data with the two agents.
Adding Ibudilast to Temozolomide Increases Apoptosis, Survival in Preclinical GBM Study
Combination therapy with ibudilast and temozolomide for glioblastoma multiforme increased apoptosis and prolonged survival by significantly reducing macrophage inhibitory factor and receptor CD74 expression.
Expert Discusses Promising ABT-414 Trial Results in EGFR-Amplified, Recurrent GBM
A phase I trial of the antibody drug conjugate ABT-414 has shown promising results for the treatment of patients with EGFR-amplified, recurrent glioblastoma.
Toca 511 Shows Promise in High-Grade Glioma
The gene for an anticancer drug was successfully transduced in high-grade gliomas, which resulted in an improvement in overall survival, according to data from a phase I trial of Toca 511.
FDA Approvals in Myeloma and aTTP, Priority Review Designations in RCC and HNSCC, and More
PARP Inhibitors Hold Promise in mCRPC and Biallelic DNA Repair Gene Defects
Novel Agents Spark New Approaches for Triple-Negative Breast Cancer
Pembrolizumab Shows Promising Activity in Non-Clear Cell RCC
Pembrolizumab/Cabozantinib Combo Is Well Tolerated, Shows Activity in Metastatic RCC
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.